166 related articles for article (PubMed ID: 19878141)
1. 5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study.
Martín-Santos R; Torrens M; Poudevida S; Langohr K; Cuyás E; Pacifici R; Farré M; Pichini S; de la Torre R
Addict Biol; 2010 Jan; 15(1):15-22. PubMed ID: 19878141
[TBL] [Abstract][Full Text] [Related]
2. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.
Reneman L; Schilt T; de Win MM; Booij J; Schmand B; van den Brink W; Bakker O
J Psychopharmacol; 2006 May; 20(3):389-99. PubMed ID: 16574713
[TBL] [Abstract][Full Text] [Related]
3. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
4. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].
Guillem E; Pelissolo A; Vorspan F; Bouchez-Arbabzadeh S; Lépine JP
Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408
[TBL] [Abstract][Full Text] [Related]
5. Major depression: the relative contribution of gender, MDMA, and cannabis use.
Durdle H; Lundahl LH; Johanson CE; Tancer M
Depress Anxiety; 2008; 25(3):241-7. PubMed ID: 17345601
[TBL] [Abstract][Full Text] [Related]
6. The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls.
Roiser JP; Rogers RD; Cook LJ; Sahakian BJ
Psychopharmacology (Berl); 2006 Oct; 188(2):213-27. PubMed ID: 16941121
[TBL] [Abstract][Full Text] [Related]
7. Pathways into ecstasy use: the role of prior cannabis use and ecstasy availability.
Zimmermann P; Wittchen HU; Waszak F; Nocon A; Höfler M; Lieb R
Drug Alcohol Depend; 2005 Sep; 79(3):331-41. PubMed ID: 15913921
[TBL] [Abstract][Full Text] [Related]
8. The impact of comorbid cannabis and methamphetamine use on mental health among regular ecstasy users.
Scott LA; Roxburgh A; Bruno R; Matthews A; Burns L
Addict Behav; 2012 Sep; 37(9):1058-62. PubMed ID: 22607716
[TBL] [Abstract][Full Text] [Related]
9. Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter.
Kuypers KPC; de la Torre R; Farre M; Xicota L; de Sousa Fernandes Perna EB; Theunissen EL; Ramaekers JG
Sci Rep; 2018 Jan; 8(1):1061. PubMed ID: 29348651
[TBL] [Abstract][Full Text] [Related]
10. Cannabis use and symptoms of anxiety in adolescence and the moderating effect of the serotonin transporter gene.
Otten R; Huizink AC; Monshouwer K; Creemers HE; Onrust S
Addict Biol; 2017 Jul; 22(4):1081-1089. PubMed ID: 26860734
[TBL] [Abstract][Full Text] [Related]
11. The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users.
Fagundo AB; Cuyàs E; Verdejo-Garcia A; Khymenets O; Langohr K; Martín-Santos R; Farré M; de la Torre R
J Psychopharmacol; 2010 Sep; 24(9):1381-93. PubMed ID: 20080926
[TBL] [Abstract][Full Text] [Related]
12. 5-HTTLPR Genotype Moderates the Effects of Past Ecstasy Use on Verbal Memory Performance in Adolescent and Emerging Adults: A Pilot Study.
Wright NE; Strong JA; Gilbart ER; Shollenbarger SG; Lisdahl KM
PLoS One; 2015; 10(7):e0134708. PubMed ID: 26231032
[TBL] [Abstract][Full Text] [Related]
13. Mental disorders in current and former heavy ecstasy (MDMA) users.
Thomasius R; Petersen KU; Zapletalova P; Wartberg L; Zeichner D; Schmoldt A
Addiction; 2005 Sep; 100(9):1310-9. PubMed ID: 16128720
[TBL] [Abstract][Full Text] [Related]
14. [Comorbidity in 207 cannabis users in a specific outpatient setting].
Guillem E; Arbabzadeh-Bouchez S; Vorspan F; Bellivier F
Encephale; 2015 Jun; 41 Suppl 1():S7-12. PubMed ID: 25123065
[TBL] [Abstract][Full Text] [Related]
15. Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
Keyes KM; Martins SS; Hasin DS
Drug Alcohol Depend; 2008 Sep; 97(1-2):139-49. PubMed ID: 18524499
[TBL] [Abstract][Full Text] [Related]
16. Club drug use in Germany.
Soellner R
Subst Use Misuse; 2005; 40(9-10):1279-93. PubMed ID: 16048817
[TBL] [Abstract][Full Text] [Related]
17. Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment.
Arendt M; Munk-Jørgensen P; Sher L; Jensen SO
Drug Alcohol Depend; 2011 Apr; 114(2-3):134-9. PubMed ID: 20971585
[TBL] [Abstract][Full Text] [Related]
18. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
[TBL] [Abstract][Full Text] [Related]
19. [Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].
Liraud F; Verdoux H
Encephale; 2002; 28(2):160-8. PubMed ID: 11972143
[TBL] [Abstract][Full Text] [Related]
20. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
Soar K; Turner JJ; Parrott AC
J Psychopharmacol; 2006 May; 20(3):417-24. PubMed ID: 16574716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
